Transcenta Holding Ltd. (6628)

Overview

Transcenta Holding Limited, initially named MabSpace International Limited, is a transformative entity in the biopharmaceutical landscape, primarily operating from its headquarters in Suzhou, the People's Republic of China, with active operations in both China and the United States. Founded in 2010 and undergoing a significant rebranding in June 2019, the company has carved its niche by focusing on the discovery, research, development, manufacturing, and commercialization of innovative drug therapies. With a strategic vision that encapsulates the clinical stage biopharmaceutical domain, Transcenta is dedicated to introducing groundbreaking treatments across a variety of diseases, thereby underscoring its collaborative endeavors with industry giants such as Eli Lilly and Company, Alebund Pharmaceuticals, Merck, and AGILENT Technologies.

Products and Services

• MSB2311: A humanized PD-L1 monoclonal antibody candidate designed to target TMB-H solid tumors, MSB2311 represents Transcenta's foray into advanced cancer therapy, focusing on enhancing the body's immune response against tumors.
• TST001: This humanized claudin 18.2 mAb candidate is undergoing Phase II clinical trials aimed at treating solid tumors, including gastric cancer, showcasing Transcenta's commitment to addressing hard-to-treat cancers.
• TST005: A PD-L1/TGF-ß bi-functional antibody candidate currently in Phase Ia clinical trials for the treatment of solid tumors, such as certain lung cancers, TST005 exemplifies Transcenta's innovative approach to cancer therapy by targeting multiple pathways.
• TST010: An antibody candidate that targets regulatory T cells to augment T cell mediated tumor destruction, TST010 underscores Transcenta's strategy of enhancing the immune system's capacity to combat cancer.
• TST002 (Blosozumab): A humanized sclerostin mAb candidate for osteoporosis, TST002 signifies Transcenta's diversification into treatments for skeletal diseases, leveraging monoclonal antibody technology.
• TST004: This humanized mannan-binding lectin serine protease 2 (MASP 2) mAb candidate is designed for IgA kidney diseases, illustrating Transcenta's venture into renal health through targeted antibody therapies.
• TST003: An antibody targeting a novel immune regulatory protein produced by tumor-associated fibroblasts or mesenchymal phenotype tumor cells, TST003 reflects Transcenta's exploration of new targets within the tumor microenvironment.
• TST006: A bi-specific claudin 18.2/PD-L1 antibody aiming to advance cancer treatment by simultaneously targeting two crucial pathways involved in tumor growth and immune evasion.
• TST008: A tri-functional antibody that combines a MASP2 antibody with a truncated transmembrane activator and CAML interactor protein, TST008 represents a novel approach in targeting inflammation and autoimmune diseases.
• MSB0254: A humanized VEGFR-2 mAb candidate under Phase Ib/IIa clinical trials for solid tumors, MSB0254 epitomizes Transcenta's efforts in inhibiting angiogenesis, a critical process in tumor growth and metastasis.